SecBot SecBot
SECBOTREPLAY Home › Report › ACRV

ACRV · Acrivon Therapeutics acquired Aqilion AB's Phase 2-ready oral JAK1…

Acrivon Therapeutics, Inc. · 8-K filed Nov 6, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Nov 6, 2026 at 08:00 ET

Acrivon Therapeutics acquired Aqilion AB's Phase 2-ready oral JAK1 inhibitor ACR-525 and a preclinical PKCθ inhibitor program for an undisclosed cash sum with no future milestone or royalty obligations. The acquisition establishes immunology and inflammation as a new strategic pillar alongside oncology, with eosinophilic esophagitis targeted as the first potential indication.

  • Acquired ACR-525 (formerly AQ280), a Phase 2-ready oral JAK1 inhibitor, and a preclinical PKCθ inhibitor program from Aqilion AB
  • Consideration was an undisclosed cash payment with no future milestone or royalty obligations
  • Concurrently terminated all future royalty and milestone obligations on ACR-525 previously agreed between Aqilion and LEO Pharma
  • Eosinophilic esophagitis (EoE) targeted as first potential indication using a formulation designed for difficulty swallowing

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access